Antibodies and antigen-binding peptides as factor XIA inhibitors, and their use

Novel antibodies and peptides targeting FXIa and plasma kallikrein inhibitors address bleeding risks and thrombus formation in thromboembolic diseases by modulating antithrombotic effects and enabling effective monitoring, enhancing safety and efficacy of treatment.

JP7863566B2Active Publication Date: 2026-05-21BRISTOL MYERS SQUIBB CO +1
2 Cites 0 Cited by

Patent Information

Application Number
JP2023541614
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2021-02-24
Filing Date
2022-01-07
Publication Date
2026-05-21
Estimated Expiration
2042-01-07

AI Technical Summary

Technical Problem

Current anticoagulant therapies for thromboembolic diseases, such as those targeting factor XIa (FXIa) and plasma kallikrein, risk bleeding complications and thrombus formation, necessitating the development of compounds that can restore antithrombotic effects without these risks.

Method used

Development of novel antibodies and antigen-binding peptides that specifically target FXIa inhibitors and/or FXIa/plasma kallikrein dual inhibitors to modulate their antithrombotic effects, along with detection reagents and methods for monitoring FXIa inhibition levels.

Benefits of technology

The antibodies and peptides effectively reduce the antithrombotic effects of FXIa inhibitors, minimizing bleeding risks and thrombus formation, while providing a means to monitor inhibitor levels in biological samples.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention provides novel antigen-binding peptides, such as antibodies or antibody fragments, that specifically bind to selective FXIa inhibitors and / or dual inhibitors of FXIa and plasma kallikrein.The present invention further relates to a method of reducing the antithrombotic effect of FXIa inhibitors by administering to a subject a pharma- ceutical effective amount of the antigen-binding peptides disclosed herein.In addition, the present invention provides detection reagents and methods for detecting FXIa inhibitor levels in biological samples. TIFF2024505390000129.tif113125
Need to check novelty before this filing date? Find Prior Art